Science is the Cure Research Symposium
Advances in understanding and treatments in Leukemia & Cellular Therapy
Clinical & Transnational Research
February 18, 2020
The Science is the Cure Research Symposium brings together leading researchers and physicians to advance the science behind the cure from molecular discoveries to innovative treatments. Bringing innovative therapies from research to the bedside, the 2020 Science is the Cure Research Symposium focuses on clinical and translational research on advances in understanding and treatments in leukemia and cellular therapy. Featured Physician Researchers will present the current developments in immune therapies for hematological malignancies, research trials investigating novel approaches, and cellular therapies in Stem Cell Transplantation.
In addition to attendees learning the latest developments in immune and cellular therapies for hematological malignancies at the Science is the Cure Research Symposium, the symposium will select 20 applicants to present their research. Each researcher will present their research and answer questions from the Scientific Advisory Board and Symposium attendees. At the end of the Symposium, the audience and the Scientific Advisory Board will select a grant recipient of $50,000 to further their research.
Interested researchers should submit their application and one page abstract by December 1, 2019. Twenty presentations will be selected to present at the Science is the Cure Research Symposium.Kids Beating Cancer awards grants to young investigators at leading institutions for early phases of oncology research with the hope of speeding up the development of clinical trials.
The Scientific Advisory Board of Kids Beating Cancer, Inc. (KBC) invites investigators, trainees, graduate students and others doing research on topics relevant to childhood cancers to submit a one-page abstract to be considered for presentation at the KBC Science is the Cure Research Symposium.
Deadline for Abstract submission is 11:59 EST December 1, 2019. Submitting an abstract from a recent research conference is acceptable. Abstracts will be reviewed by the KBC Scientific Advisory Board to determine presenters for the Symposium. Notification of selected abstracts will be in mid-June.
Call for Abstracts for the Kids Beating Cancer 2020 Science is the Cure Research Symposium
The Scientific Advisory Board of Kids Beating Cancer (KBC) 2019 Science is the Cure Research Symposium invites investigators doing research on topics to submit an abstract for consideration to be presented at the KBC Research Symposium.
Scientific Advisory Board & Speakers
Jeffrey E. Rubnitz, MD, PhD Chief, Leukemia / Lymphoma Division – St. Jude Children’s Research Hospital
Dr. Jeffrey Rubnitz is a board certified in Pediatric Hematology-Oncology and pediatrics. Rubnitz serves as the Chief of the Leukemia and Lymphoma division at St. Jude’s Research Hospital.He received his Medical Doctorate and PhD from the University of California at San Diego.Dr. Rubnitz’s main interest is in developing new strategies for the treatment of acute myeloid leukemia (AML). His new AML protocol (AML08) will determine if the combination of clofarabine and cytarabine is as effective as standard induction with cytarabine, daunomycin, and etoposide; and will test whether the infusion of haploidentical natural killer cells can reduce relapse rates. He also explores novel therapies for certain high risk groups and continues studies of minimal residual disease and genome-wide analysis in AML. Dr. Rubnitz has published over 30 papers.
David Shook, MD Medical Director – Kids Beating Cancer Pediatric Transplant Center at AdventHealth for Children
David Shook, MD, is a board-certified pediatrician and pediatric hematologist-oncologist who treats patients while serving as the Medical Director of AdventHealth for Children’s world-renowned Pediatric Bone Marrow Transplant Program. He is a leading expert in the treatment of children with blood and bone disorders, and he specializes in bone marrow transplants and cellular therapy. A noted researcher and recipient of a National Institutes of Health Research Service Award, Dr. Shook attended medical school and completed his residency training at Johns Hopkins University, where he was recognized with the Harrison Award for Proficiency in Pediatrics. He also completed two advanced fellowships – one in pediatric hematology and oncology and the other in bone marrow transplantation and cellular therapy – at St. Jude Children’s Research Hospital.
Steve Goldstein, MD – Cell Therapy, Hematology and Oncology
Steven Goldstein, MD, is board certified in internal medicine with a subspecialty certification in oncology. He received his medical degree from the University of Pittsburgh School of Medicine, and completed his residency in Internal Medicine and fellowship in Hematology/Oncology at the University of Michigan Medical Center in Ann Arbor. Dr. Goldstein has published over 50 peer-reviewed publications, 7 book chapters and over 90 abstracts. He most recently has been an Associate Professor at the University of Michigan Hospital and Health Systems and has served as Principal Investigator for several research trials investigating novel approaches and cellular therapies in Stem Cell Transplantation.
Juan Carlos Valera, MD – Hematology and Oncology
Dr. Juan Carlos Varela obtained his MD/PhD from the Medical University of South Carolina in 2010. He completed his residency training in internal medicine at the Osler medical training program at Johns Hopkins Hospital, followed by fellowship training in hematology at the Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. Dr. Varela’s clinical interests include novel immune therapies for hematological malignancies and bone marrow transplantation and treatments for leukemia, lymphoma and multiple myeloma. He is the principal investigator for numerous national clinical trials.
James Baumgartner, MD Surgical Director – Comprehensive Pediatric Epilepsy Center & Neurosurgery
James Baumgartner, MD, is a board-certified pediatric neurosurgeon with more than two decades of experience providing minimally invasive surgical procedures to help children who experience seizures associated with epilepsy or other neurosurgical disorders. He consults with patients and their parents at AdventHealth Medical Group’s neurosurgery practice next to AdventHealth Orlando and is the Surgical Director of AdventHealth for Children’s Comprehensive Pediatric Epilepsy Center. Dr. Baumgartner is an eminently qualified physician whose outstanding credentials include his post-graduate degree in pharmacology from Cambridge University in England, his medical degree from the University of Michigan in Ann Arbor and his neurosurgical residency and pediatric neurosurgery fellowship training at the University of California – San Francisco.
Fouad Hajjar, MD – Medical Director of Pediatric Hematology and Oncology
Dr. Fouad Hajjar is board certified in pediatrics and pediatric hematology and oncology. He has over 20 years of experience, including serving as the Medical Director of the Pediatric Oncology and Hematology at the AdventHealth Cancer Institute of Orlando . He received his medical degree from St. Joseph’s University Medical School in Beirut, Lebanon, and completed his residency at Buffalo Children’s Hospital in New York followed by his pediatric hematology/oncology fellowship at Yale. He is the current Chairman of the AdventHealth Institutional Review Board, the Central Florida Chapter of the Leukemia and Lymphoma Society and the Perinatal and Pediatric Ethics Committee. He is also a member of the board of the St. Jude Children’s Research Hospital.
The KBC 2020 Science is the Cure Research Symposium invites uniquely submitted abstracts or previously submitted abstracts from recent prominent research conferences, such as ASPHO, ASH, ASCO, or AACR. It is understood that any individual abstract may be part of an on-going project.
We request that the Abstract include the following:
- Descriptive title,
- Listing of authors and associated institutions,
- Description of research and a concise summary of findings within a 400-word limit,
- no graphics or diagrams,
- To address how the research is being undertaken, the value of the its findings, and to whom will they impact.
Grant recipient direct costs may include salary, research supplies and equipment. Equipment costs must be less than $5,000 and not be administrative in nature. Grant funding MAY NOT be used for indirect costs such as travel associated with the research, administrative supplies, advertising or PR, student or university memberships and parking or other facility-related fees. Applicants MAY be involved in other research grants, but there must be clear documentation of mechanisms to avoid scientific and/or budgetary overlap.
When: February 18, 2020
Where: Marriott World Center, Orlando, FL
Abstract Deadline: December 1, 2019
Registration Deadline: January 15, 2020
Selected applicants: waived
Symposium attendees: $75
Marriott World Center
8701 World Center Dr, Orlando, FL 32821